Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sebastian Schneeweiss, Sc.D., M.D.

Co-Author

This page shows the publications co-authored by Sebastian Schneeweiss and Shirley Wang.
Connection Strength

6.781
  1. Assessing and Interpreting Real-World Evidence Studies: Introductory Points for New Reviewers. Clin Pharmacol Ther. 2021 Aug 20.
    View in: PubMed
    Score: 0.982
  2. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ. 2021 01 12; 372:m4856.
    View in: PubMed
    Score: 0.942
  3. Graphical Depiction of Longitudinal Study Designs in Health Care Databases. Ann Intern Med. 2019 03 19; 170(6):398-406.
    View in: PubMed
    Score: 0.829
  4. Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology. 2013 May; 24(3):375-8.
    View in: PubMed
    Score: 0.552
  5. Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes. Diabetes Obes Metab. 2020 04; 22 Suppl 3:45-59.
    View in: PubMed
    Score: 0.223
  6. Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes. JAMA Netw Open. 2020 01 03; 3(1):e1918962.
    View in: PubMed
    Score: 0.219
  7. Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure. Circ Cardiovasc Qual Outcomes. 2018 12; 11(12):e004700.
    View in: PubMed
    Score: 0.203
  8. Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic. Epidemiology. 2018 11; 29(6):895-903.
    View in: PubMed
    Score: 0.202
  9. Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials. Clin Pharmacol Ther. 2019 05; 105(5):1156-1163.
    View in: PubMed
    Score: 0.201
  10. Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. Am J Epidemiol. 2018 08 01; 187(8):1799-1807.
    View in: PubMed
    Score: 0.199
  11. Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiol Drug Saf. 2018 06; 27(6):567-569.
    View in: PubMed
    Score: 0.195
  12. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2018 04; 27(4):383-390.
    View in: PubMed
    Score: 0.192
  13. A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies. Pharmacoepidemiol Drug Saf. 2017 Dec; 26(12):1507-1512.
    View in: PubMed
    Score: 0.188
  14. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Value Health. 2017 09; 20(8):1009-1022.
    View in: PubMed
    Score: 0.187
  15. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiol Drug Saf. 2017 09; 26(9):1018-1032.
    View in: PubMed
    Score: 0.186
  16. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016 May 24; 353:i2607.
    View in: PubMed
    Score: 0.171
  17. Optimal matching ratios in drug safety surveillance. Epidemiology. 2014 Sep; 25(5):772-3.
    View in: PubMed
    Score: 0.151
  18. "First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. Am J Epidemiol. 2014 Sep 15; 180(6):636-44.
    View in: PubMed
    Score: 0.151
  19. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiol Drug Saf. 2014 Jun; 23(6):619-27.
    View in: PubMed
    Score: 0.148
  20. A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes. Endocrinol Diabetes Metab. 2021 Jul; 4(3):e00237.
    View in: PubMed
    Score: 0.060
  21. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Pharmacoepidemiol Drug Saf. 2020 11; 29(11):1504-1513.
    View in: PubMed
    Score: 0.058
  22. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. Value Health. 2020 09; 23(9):1128-1136.
    View in: PubMed
    Score: 0.057
  23. Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model. Clin Epidemiol. 2020; 12:607-616.
    View in: PubMed
    Score: 0.057
  24. Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles. Epidemiology. 2020 01; 31(1):82-89.
    View in: PubMed
    Score: 0.055
  25. CMAJ. 2019 06 24; 191(25):E689-E708.
    View in: PubMed
    Score: 0.053
  26. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018 Nov 14; 363:k3532.
    View in: PubMed
    Score: 0.051
  27. Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations. Eur J Epidemiol. 2018 Jun; 33(6):545-555.
    View in: PubMed
    Score: 0.049
  28. Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. Clin Pharmacol Ther. 2018 11; 104(5):1008-1015.
    View in: PubMed
    Score: 0.048
  29. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value Health. 2017 09; 20(8):1003-1008.
    View in: PubMed
    Score: 0.047
  30. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017 Sep; 26(9):1033-1039.
    View in: PubMed
    Score: 0.047
  31. Initiation patterns of statin therapy among adult patients undergoing intermediate to high-risk non-cardiac surgery. Pharmacoepidemiol Drug Saf. 2016 Jan; 25(1):64-72.
    View in: PubMed
    Score: 0.041
  32. Patterns of ß-blocker initiation in patients undergoing intermediate to high-risk noncardiac surgery. Am Heart J. 2015 Oct; 170(4):812-820.e6.
    View in: PubMed
    Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.